Dexcom
Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
DitchCarbon Score
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dexcom's score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dexcom's reported carbon emissions
In 2023, Dexcom reported total carbon emissions of approximately 25,291,000 kg CO2e, with emissions distributed across various scopes: 3,400,000 kg CO2e from Scope 1 (including both mobile and stationary combustion), 25,291,000 kg CO2e from Scope 2, and 7,748,000 kg CO2e from Scope 3 (including business travel and waste generated in operations). Over the past few years, Dexcom has shown a trend in emissions, with 2022 emissions at about 13,610,000 kg CO2e for Scope 2 and 1,749,000 kg CO2e for Scope 3. In 2021, the company reported 11,807,000 kg CO2e for Scope 2 and 1,587,000 kg CO2e for Scope 3. The data indicates a significant increase in emissions in 2023 compared to previous years, particularly in Scope 2 emissions. Dexcom has committed to near-term emissions reduction targets, although specific numerical targets have not been disclosed. The company is not currently committed to a net-zero target. Their climate commitments reflect a growing awareness of sustainability within the healthcare equipment sector, aligning with industry standards for emissions reporting and reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,903,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,257,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
